Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Portfolio Pulse from Vandana Singh
Regeneron Pharmaceuticals (NASDAQ:REGN) released promising Phase 1 data on garetosmab and trevogrumab, showing significant improvements in body composition. Goldman Sachs maintains a Buy rating with a $1,180 price target. Regeneron is also conducting a Phase 2 study with Novo Nordisk's (NYSE:NVO) semaglutide. REGN shares are up 1.29%.
June 24, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron is conducting a Phase 2 study with Novo Nordisk's semaglutide to evaluate improvements in weight loss quality. This collaboration could enhance Novo Nordisk's market position in obesity treatments.
The collaboration with Regeneron on a Phase 2 study could enhance Novo Nordisk's market position in obesity treatments, potentially leading to positive investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Regeneron Pharmaceuticals released positive Phase 1 data on garetosmab and trevogrumab, showing significant improvements in body composition. Goldman Sachs maintains a Buy rating with a $1,180 price target. REGN shares are up 1.29%.
The positive Phase 1 data and the Buy rating from Goldman Sachs with a high price target are likely to boost investor confidence in Regeneron. The ongoing Phase 2 study further adds to the potential for future gains.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100